Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Pompe disease is a lysosomal storage disorder caused by acid-α-glucosidase (GAA) deficiency, leading to glycogen storage. The disease manifests as a fatal cardiomyopathy in infantile form. Enzyme replacement therapy (ERT) has recently prolonged the lifespan of these patients, revealing a new natural history. The neurologic phenotype and the persistence of selective muscular weakness in some patients could be attributed to the central nervous system (CNS) storage uncorrected by ERT. GAA-KO 6neo/6neo mice were treated with a single intrathecal administration of adeno-associated recombinant vector (AAV) mediated gene transfer of human GAA at 1 month and their neurologic, neuromuscular, and cardiac function was assessed for 1 year. We demonstrate a significant functional neurologic correction in treated animals from 4 months onward, a neuromuscular improvement from 9 months onward, and a correction of the hypertrophic cardiomyopathy at 12 months. The regions most affected by the disease i.e. the brainstem, spinal cord, and the left cardiac ventricular wall all show enzymatic, biochemical and histological correction. Muscle glycogen storage is not affected by the treatment, thus suggesting that the restoration of muscle functionality is directly related to the CNS correction. This unprecedented global and long-term CNS and cardiac cure offer new perspectives for the management of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J., & Jude Samulski, R. (2013) · Gene Therapy · doi:10.1038/gt.2012.101 · Cited by 377 · cited 3×
“The feasibility of AAV-mediated gene transfer via the CSF in large animal models and non-human primates has been largely demonstrated by we [3, 4], and others [19, 25, 27, 28, 41, 42, 49, 50].”
BackgroundAdeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates
Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas, J. R., Lamarre, C., Forsayeth, J., Kaspar, B. K., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.200 · Cited by 299 · cited 1×
“The feasibility of AAV-mediated gene transfer via the CSF in large animal models and non-human primates has been largely demonstrated by we [3, 4], and others [19, 25, 27, 28, 41, 42, 49, 50].”
BackgroundMeyer, K., Ferraiuolo, L., Schmelzer, L., Braun, L., McGovern, V., Likhite, S., Michels, O., Govoni, A., Fitzgerald, J., Morales, P., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.210 · Cited by 286
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66778 · Cited by 215
Smith, B. K., Collins, S. W., Conlon, T. J., Mah, C. S., Lawson, L. A., Martin, A. D., Fuller, D. D., Cleaver, B. D., Clément, N., Phillips, D., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.250 · Cited by 158
Byrne, B. J., Falk, D. J., Pacak, C. A., Nayak, S., Herzog, R. W., Elder, M. E., Collins, S. W., Conlon, T. J., Clement, N., Cleaver, B. D., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr174 · Cited by 91
Bucher, T., Dubreil, L., Colle, M.-A., Maquigneau, M., Deniaud, J., Ledevin, M., Moullier, P., & Joussemet, B. (2014) · Gene Therapy · doi:10.1038/gt.2014.16 · Cited by 40 · cited 3×
“The feasibility of AAV-mediated gene transfer via the CSF in large animal models and non-human primates has been largely demonstrated by we [3, 4], and others [19, 25, 27, 28, 41, 42, 49, 50].”
BackgroundSelf-citationCorti, M., Smith, B. K., Falk, D. J., Lawson, L. A., Fuller, D. D., Subramony, S. H., Byrne, B. J., & Christou, E. A. (2015) · Muscle & Nerve · doi:10.1002/mus.24444 · Cited by 20 · cited 2×
“Neither AAV transduction, nor GAA activity in muscles has been reported in our study after AAV9 or 10 treatments, highlighting the neurogenic muscle weakness and the pathology of the neuromuscular junction also reported by others [15, 24, 63].”
Background
Cited by
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
Prasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
Palazzi, X., Pardo, I. D., Sirivelu, M. P., Newman, L., Kumpf, S. W., Qian, J., Franks, T., Lopes, S., Liu, J., Monarski, L., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.116 · Cited by 60
“Use of tissue-specific promoters to restrict transgene expression and the natural tropism of viral capsids to selective tissues has been exploited to restore factor VIII or IX expression in hepatocytes, neurons, or myofibers for specific disease entities such a spinal muscular atrophy or Duchenne’s muscular dystrophy.…”
BackgroundPompe disease gene therapy: neural manifestations require consideration of CNS directed therapy
Byrne, B. J., Fuller, D. D., Smith, B. K., Clement, N., Coleman, K., Cleaver, B., Vaught, L., Falk, D. J., McCall, A., & Corti, M. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.56 · Cited by 51
Hordeaux, J., Ramezani, A., Tuske, S., Mehta, N., Song, C., Lynch, A., Lupino, K., Chichester, J. A., Buza, E. L., Dyer, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094279 · Cited by 23
Self-citation
Metadata
- Authors
- Hordeaux, J., Dubreil, L., Robveille, C., Deniaud, J., Pascal, Q., Dequéant, B., Pailloux, J., Lagalice, L., Ledevin, M., Babarit, C., Costiou, P., Jamme, F., Fusellier, M., Mallem, Y., Ciron, C., Huchet, C., Caillaud, C., & Colle, M.-A.
- Venue
- Acta Neuropathologica Communications
- Published
- 2017-09-06
- Volume
- 5
- Issue
- 1
- Pages
- 66-66
- ISSN
- 2051-5960 (ISSN-L)
- OpenAlex
- W2753413345
- Cited by
- 59
- References
- 8
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. https://app.cochat.ai/papers/10.1186/s40478-017-0464-2
- The paper
- Hordeaux, J., Dubreil, L., Robveille, C., Deniaud, J., Pascal, Q., Dequéant, B., Pailloux, J., Lagalice, L., Ledevin, M., Babarit, C., Costiou, P., Jamme, F., Fusellier, M., Mallem, Y., Ciron, C., Huchet, C., Caillaud, C., & Colle, M.-A. (2017). Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-017-0464-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.